Your browser doesn't support javascript.
loading
Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
Yamamoto, Yoshiaki; Loriot, Yohann; Beraldi, Eliana; Zhang, Fan; Wyatt, Alexander W; Al Nakouzi, Nader; Mo, Fan; Zhou, Tianyuan; Kim, Youngsoo; Monia, Brett P; MacLeod, A Robert; Fazli, Ladan; Wang, Yuzhuo; Collins, Colin C; Zoubeidi, Amina; Gleave, Martin.
Affiliation
  • Yamamoto Y; The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan.
  • Loriot Y; The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Beraldi E; The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Zhang F; The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Wyatt AW; The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Al Nakouzi N; The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Mo F; The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Zhou T; Department of Antisense Drug Discovery, Isis Pharmaceuticals Inc., Carlsbad, California.
  • Kim Y; Department of Antisense Drug Discovery, Isis Pharmaceuticals Inc., Carlsbad, California.
  • Monia BP; Department of Antisense Drug Discovery, Isis Pharmaceuticals Inc., Carlsbad, California.
  • MacLeod AR; Department of Antisense Drug Discovery, Isis Pharmaceuticals Inc., Carlsbad, California.
  • Fazli L; The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Wang Y; The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Collins CC; The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Zoubeidi A; The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Gleave M; The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. m.gleave@ubc.ca.
Clin Cancer Res ; 21(7): 1675-87, 2015 Apr 01.
Article in En | MEDLINE | ID: mdl-25634993
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylthiohydantoin / Receptors, Androgen / Oligonucleotides, Antisense / Drug Resistance, Neoplasm / Prostatic Neoplasms, Castration-Resistant / Antineoplastic Agents Limits: Animals / Humans / Male Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2015 Type: Article Affiliation country: Japan
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylthiohydantoin / Receptors, Androgen / Oligonucleotides, Antisense / Drug Resistance, Neoplasm / Prostatic Neoplasms, Castration-Resistant / Antineoplastic Agents Limits: Animals / Humans / Male Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2015 Type: Article Affiliation country: Japan